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Brugada syndrome (BrS) is characterized by coved-type ST-
segment elevation in the right precordial leads of electro-
cardiogram (ECG) and the development of ventricular
ﬁbrillation (VF) leading to sudden cardiac death.1,2 Inher-
itance of BrS occurs via an autosomal-dominant mode of
transmission. The ﬁrst gene linked to BrS is SCN5A, the gene
that encodes the alpha subunit of the cardiac sodium
channel.3 SCN5A mutations, mainly loss-of-function, have
been identiﬁed in 10%–28% of BrS probands in 9 interna-
tional centers around the world.4 Over 300 mutations in
SCN5A have been linked to BrS.5
SCN5A mutations are associated with both BrS and
familial atrial ﬁbrillation, progressive cardiac conduction
defect, sick sinus syndrome, early repolarization syndrome,
dilated cardiomyopathy, and sudden infant death syndrome.6
Furthermore, BrS has been linked to mutations in 18 other
genes, but they are rarer. Thus, BrS is often genetically
undetermined and the genotype-phenotype correlations are
not completely matched, even in SCN5A mutation–positive
BrS families.7,8
Recently, we have identiﬁed IRX3 mutation as a genetic
risk factor of idiopathic VF, including BrS without SCN5A
mutation.9 Here we present the ﬁrst case reportKEYWORDS Brugada syndrome; Genes; IRX3; SCN5A; Ventricular ﬁbrillation
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variant accentuated the Brugada phenotype, inducing
repetitive VF.
Case report
Patient
A 35-year-old man was admitted to our hospital after
successful resuscitation of cardiac arrest caused by VF in
1989. His past history was noncontributory, with no familial
history involving sudden cardiac death. He was initially
diagnosed with idiopathic VF, and there had been no
episodes in 15 years following treatment with disopyramide.
He was subsequently diagnosed with BrS on the basis of
spontaneous type 1 Brugada ECG, which was more pro-
nounced in the third intercostal space (Figure 1A), and
received an implantable cardioverter-deﬁbrillator in 1998.
When he was 50 years old, he underwent 4 successful
implantable cardioverter-deﬁbrillator interventions for VF
(Figure 1B). Denopamine was added and effectively
reduced premature ventricular complexes, especially at
nighttime. VF episodes then decreased to 0–2 times per
year. At the age of 60, however, he experienced multiple
VF episodes, including a VF storm, despite the combina-
tion therapy with disopyramide (450 mg/day), denopamine
(15 mg/day), and cilostazol (200 mg/day). Quinidine
was considered but not used, because disopyramide, which
has a similar effect of suppressing the transient out-
ward potassium (Ito) current, may have already been
ineffective.
Genetic study
We examined the sequence of exons in 13 proposed BrS-
related genes in humans (SCN5A, GPD1-L, CACNA1C,
CACNB2, KCNE3, SCN1B, SCN3B, KCNJ8, MOG1,
HCN4, KCND3, KCNE5, and SLMAP) and found 1 SCN5A
mutation, 2205C4T (A735V), in the patient (proband) andpen access article under the CC BY-NC-ND license
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KEY TEACHING POINTS
 IRX3 gene, even if it is not a mutation but also a
variant, may act as a modiﬁer of Brugada syndrome
(BrS) and ventricular ﬁbrillation (VF) storm.
 SCN5A mutations probably act as a major
modulating factor in revealing the BrS phenotype.
 BrS and its VF episodes are likely due to multiple
mechanisms.
Heart Rhythm Case Reports, Vol 2, No 6, November 2016466his father and son. The SCN5A-A735V has already been
reported as causing BrS, a sudden unexplained nocturnal
death syndrome.10
Even though the proband’s father and son have the same
SCN5A mutation, their ECGs did not show BrS and they had
no symptoms or ventricular arrhythmias (his father had atrial
ﬁbrillation) (Figure 1C). Therefore, we further examined the
IRX3 gene, which we had reported as a risk factor of
idiopathic VF9 in this family. The proband carried the
IRX3 2207G4T (Q479H) variant in addition to the SCN5A
mutation, (A735V). The patient’s father and son, who had
the same SCN5A-A735V mutation, did not have the IRX3
Q479H variant. In contrast, his mother and daughter, who
did not have the SCN5A mutation, had the IRX3 2207G4T
(Q479H) variant (Figure 2A). None of these 4 family
members had the Brugada ECG or episodes of syncope,
ventricular tachyarrhythmias, or sudden cardiac death. Thus,3rd ICS4th ICS
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Figure 1 A: Surface electrocardiogram (ECG) of the proband in the fourth and th
and V2 (arrows), which was more pronounced in the third ICS than the fourth ICS.
in the proband. Premature ventricular complexes developed immediately before the
SCN5A A735V mutation. In those with available ECG recordings, V1- and V2-lea
subjects.the IRX3 2207G4T (Q479H) variant appears to act as a
modiﬁer in BrS.Discussion
Inheritance of BrS occurs via an autosomal-dominant mode
of transmission, and more than 13 responsible genes have
been associated with BrS. Genetic abnormalities are only
found in one-third of BrS patients. Even SCN5A, the ﬁrst and
most well-documented gene, accounts for less than 30% of
clinically diagnosed BrS patients.4 The penetrance of BrS is
thus considered to be low. SCN5A mutation carriers had, on
average, longer PR and QRS intervals than noncarriers,
demonstrating that these mutations exerted functional
effects.8 A recent genome-wide association study revealed
the 3 genes, SCN10A, SCN5A, and HEY2, as risk factors of
the Brugada phenotype.11 Therefore, SCN5A mutations
probably act as major modulating factors in revealing BrS.
BrS is likely an oligogenic disease, and is not considered a
monogenic Mendelian disease.12
A previous Xenopus oocytes patch clamp study demon-
strated that SCN5A A735V mutant expressed current with
steady-state activation voltage shifted to more positive
potentials and that slower recovery from inactivation resulted
in reduced sodium channel current.10 These ﬁndings are
consistent with the QRS interval prolongation in the proband
and family members with SCN5A A735V (Figure 1A),
although only the proband suffered lethal arrhythmias due
to BrS. Irx3/IRX3 encodes a transcription factor speciﬁcallyV1
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Figure 2 A: DNA sequence analysis results of the proband. The arrow
indicates a heterozygous variant in the IRX3 gene (Q479H). B:Homology of
human IRX3 and murine Irx3. Amino acids sequence conserved between
human IRX3 and mouse Irx3 was highly conserved between human IRX3
and mouse Irx3. C: Effects of transfection of HL-1 cells with Irx3 in
pcDNA3.1 vector on the expression of SCN5A. The expression of SCN5A
was normalized to that of Irx3. Wild-type Irx3 increased the mRNA
expression of SCN5A, whereas Irx3-Q485H (human Q479H) did not
increase the SCN5A mRNA expression. *P o .05 vs control.
467Kimura et al IRX3 and VF Storm in Brugada Syndromeexpressed in the His-Purkinje system in the heart.13 Genetic
deletion of Irx3 in a mouse model shows ventricular fast
conduction disturbance without anatomical or contraction
abnormalities. We recently reported the link between the
perturbed His-Purkinje system and idiopathic VF in Irx3-null
mice, and IRX3 mutations are associated with idiopathic VF
patients, including BrS without SCN5A or other Brugada-
related mutations.9 It remains unclear how IRX3 variants
contribute to the manifestation of BrS and the risk of VF or
sudden cardiac death.
To show the functional differences of mRNA expression
in SCN5A by IRX3 variants, we performed transfection of
wild-type (WT) or Q485H (human Q479H, Figure 2B) Irx3
in pcDNA3.1 vector into HL-1 cells as shown previously.9
The transfection of WT Irx3 increased the expression of
SCN5A mRNA; however, Q485H variant did not increase
the SCN5A mRNA expression as much as the WT
(Figure 2C). Thus, a common variant, Irx3 Q479H, might
be one of the modiﬁers for BrS as a cause of relative
downregulation of mRNA expression in SCN5A.
The 2207G4T (Q479H) is a common variant in a
chaperone binding domain of IRX3 that was identiﬁed as
“benign” by PolyPhen-2, found in 16.8% in the 1000
genome project and 22%–23% in Europeans but 2.1% inEast Asians by ExAC. In the Japanese population, the
frequency of the 2207 G4T variant was 3.1% (4/130) in
idiopathic VF cases but 0.4% (1/250) in control subjects.
Although the precise explanation for 2207G4T remains
unknown, it may be due to ethnic differences. In this family,
the only proband has both SCN5A mutation and IRX3
variant, which is likely why he has the Brugada ECG with
repetitive VF episodes. These ﬁndings suggest that the IRX3
gene, even if it is also a variant and not a mutation, may act as
a modiﬁer of the BrS and VF storm. However, it might be
speciﬁed to the group of the Japanese population but not a
large population.
This study did not completely exclude all other possible
modiﬁers; additional (or unknown) factors such as SCN10A
or HEY2 genes could be involved as well in the clinical
presentation of the patient. However, the role of rare variants
in SCN10A and HEY2 on the BrS phenotype remain
controversial.14 The proband had suffered a VF storm when
elderly. Age-dependent conduction abnormalities due to the
patient’s genetic background are strongly associated with the
development of VF storm. Further genetic studies are
necessary to investigate the role of the IRX3 gene and other
candidate genes in the risk of VF storm in BrS.
In conclusion, IRX3 variant Q479H may play a critical
role as a modiﬁer for BrS-related frequent VF events in
SCN5A mutation–positive subjects.Acknowledgments
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